Understand the source comparison
Best PE-22-28 Dosage for Anxiety: Research Protocol Comparison
Rodent elevated plus maze (2020 Neuropeptides study) 1–3mg/kg subcutaneous Subcutaneous injection 30–60 minutes post-dose 2–4 hours 1mg/kg produced statistically significant anxiety reduction without ceiling effect at 3mg/kg. Optimal therapeutic dose likely at
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rodent elevated plus maze (2020 Neuropeptides study)
- 1–3mg/kg subcutaneous
- Subcutaneous injection
- 30–60 minutes post-dose
- 2–4 hours
- 1mg/kg produced statistically significant anxiety reduction without ceiling effect at 3mg/kg. Optimal therapeutic dose likely at lower end of range
- Human-equivalent allometric scaling
- 5.6–28mg total dose (0.08–0.4mg/kg for 70kg adult)
- Theoretical subcutaneous
- Unknown. No human data
- Provides theoretical starting range but doesn't account for species differences in receptor density or bioavailability. Phase 1 trials required
- Intranasal pilot study (2021)
- 0.5–2mg absolute dose
- Intranasal spray
- 15–30 minutes post-dose
- 1.5–3 hours
- 60% bioavailability of subcutaneous route with faster onset but shorter duration. Potentially useful for acute situational anxiety rather than sustained daily management
- Twice-daily rodent protocol
- 1mg/kg BID (morning and evening)
- Sustained across 24-hour period
- Maintained with repeated dosing
- Twice-daily dosing maintained receptor upregulation without tolerance development over 14-day study period. Suggests chronic use feasibility